Most recent update: Thursday, November 30, 2017 - 11:56

Bariatric News - Cookies & privacy policy

You are here

Gastric bypass

Understanding how GPB works - SWATH proteomics workflow

Developing network-based algorithms to handle time-series 'omics' data will be imperative for unravelling complex cause-and-effect relationships

A study by a team of researchers at the Massachusetts General Hospital Center for Engineering in Medicine (MGH-CEM) and Shriners Hospital for Children has made a technological advancement toward accelerating the discovery of drug targets for obesity, type II diabetes and other metabolic diseases. The novel experimental and computational workflow involves the first use of rodent gastric bypass models, state-of-the-art mass spectrometry and an array of bioinformatics tools to begin unravelling how gastric bypass surgery leads to weight loss and a resolution of type 2 diabetes. Their report on the impact of the surgery on liver metabolism, ‘Multi-omic network-based interrogation of rat liver metabolism following gastric bypass surgery featuring SWATH proteomics’, was published in the journal Technology.

"The therapeutic effects of gastric bypass give us hope that we can discover novel drugs for obesity and diabetes" said Dr Nima Saeidi of the MGH-CEM, principal investigator on the project. "Our goal is to reverse engineer the weight loss and resolution of blood sugar control without having to perform such an invasive procedure. To achieve this, we must first be able to capture how metabolic organs such as the liver, muscle, adipose tissue and even the small intestine reprogram themselves post-surgery to trigger the weight loss and reversal of insulin resistance"

To tackle this challenge, the team has been exploiting rapid advancements in mass spectrometry to effectively quantify thousands of biomolecules, namely metabolites and proteins, in order to obtain clues about how specific tissues or whole organs respond to gastric bypass. In the present study, they utilized the state-of-the art SWATH proteomics workflow to discover approximately 100 proteins in rat livers, levels of which were significantly affected by Roux-en-Y gastric bypass (RYGB) surgery.

These included proteins involved in iron transport, lipid metabolism and bile acid conjugation, some of which may be drugable targets for metabolic disease using a liver-specific version of the gene silencing technology RNAi. Having demonstrated the utility of this platform, the team plans to expand the analysis to study the effects of RYGB on multi-organ cross-talk via proteins secreted into the bloodstream.

"We have finally reached a stage in biomedical research where we can interrogate complex in vivo systems by cost effectively acquiring large scale mRNA, protein and metabolite data,” said Dr Gautham Vivek Sridharan. “The challenge remains in the interpretation of these high-dimensional data to provide biological insight on how tissue-specific metabolic and signaling pathways are triggered by the surgery."

In the study, Sridharan pursued a network-based approach to integrate the protein and metabolite data to discover sub-networks or modules impacted by the surgery that may not have been intuitive based on conventional textbook pathways.

"Going forward, developing network-based algorithms to handle time-series 'omics' data will be imperative for unravelling complex cause-and-effect relationships, such as the impact of post-surgery plasma hormone levels on tissue transcriptional reprogramming," he added.

Dr Martin Yarmush, director of the MGH-CEM and co-corresponding author of the paper, stresses the multi-disciplinary nature of the work: "Investigators in the field have long sought after this type of multi-omic analysis on a rodent gastric bypass model to study metabolic disease, but the work required expertise in rodent surgery, multi-omic analytics, and computational biology. At the CEM, we enable engineering scientists to tackle complex problems in biomedicine at a world-class research hospital in collaboration with clinicians. This work will likely be of great interest to biotechnology companies aspiring to build their drug pipeline in the metabolic disease area."

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.